Viveve Medical, Inc. (VIVE)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Oct 23, 2025, 8:00 PM EDT
Viveve Medical Revenue
Viveve Medical had revenue of $1.68M in the quarter ending September 30, 2022, with 4.21% growth. This brings the company's revenue in the last twelve months to $6.83M, up 2.38% year-over-year. In the year 2021, Viveve Medical had annual revenue of $6.43M with 17.28% growth.
Revenue (ttm)
6.83M
Revenue Growth
+2.38%
P/S Ratio
0.00
Revenue / Employee
145.23K
Employees
47
Market Cap
1.08K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 6.43M | 947.00K | 17.28% |
| Dec 31, 2020 | 5.48M | -1.09M | -16.57% |
| Dec 31, 2019 | 6.57M | -11.95M | -64.54% |
| Dec 31, 2018 | 18.52M | 3.23M | 21.12% |
| Dec 31, 2017 | 15.29M | 8.15M | 114.09% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| Nuo Therapeutics | 1.95M |
| Northwest Biotherapeutics | 1.09M |
Viveve Medical News
- 3 years ago - Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence - Accesswire
- 3 years ago - Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded - Accesswire
- 3 years ago - Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Accesswire
- 3 years ago - Viveve Medical, Inc. (VIVE) Q3 2022 Earnings Call Transcript - Seeking Alpha
- 3 years ago - Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update - Accesswire
- 3 years ago - Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022 - Accesswire
- 3 years ago - Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence - Accesswire
- 3 years ago - Viveve to Participate in Ladenburg Thalmann Healthcare Conference - Accesswire